Pfizer recently published the results to its Phase 3 study of BeneFIX Coagulation Factor IX (recombinant) 100 IU/kg prophylaxis compared to on-demand treatment for patients with moderately severe or severe hemophilia B. Read More »
The U.S. Food and Drug Administration (FDA) recently approved a new indication for the Novartis drug, Afinitor (everolimus). Read More »
Actinium Pharmaceuticals announced this week that its choice for Clinical Research Organization (CRO) that will conduct its Phase 3 Iomab-B clinical trial is Medpace. Read More »
Acorda Therapeutics Inc. announced last week that the waiting period has expired for its tender offer for Biotie Therapies, according to an amendment to the Hart-Scott-Rodino Antitrust Improvement Act of 1976 (HSR). Read More »
Pfizer Inc. announced last week that the United States Food and Drug Administration (FDA) has approved the expanded use of the drug IBRANCE (palbociclib). Read More »
Bristol-Myers Squibb announced today that it has finalized the sale of its HIV R&D portfolio to ViiV Healthcare. Read More »
Actinium Pharmaceuticals announced this week that it will be sending personnel from clinical and business development to the annual BMT Tandem Meetings held by the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society of Blood and Marrow Transplantation (ASBMT). Read More »
Pfizer has announced that an agreement has been reached by its subsidiary, Wyeth, to resolve claims that its practice in calculating Medicaid rebates violated the Federal Civil False Claims Act and other laws. Read More »
Sandoz, a company owned by Novartis, announced last week that it has procured the rights to develop and commercialize PF_06438179 (infliximab) from Pfizer. Read More »
Sandoz announced this week that the Marketing Authorization Application (MAA) for its biosimilar to Amgen’s EU-licensed Neulasta (pegfilgrastim) has been accepted by the European Medicines Agency (EMA). Read More »
Pfizer Inc. has commended the United States Food and Drug Administration (FDA) Arthritis Advisory Committee for its recommendation to approve the biosimilar infliximab (CT-P13) this week. Read More »
Bristol-Myers Squibb and Pfizer announced this week that the companies have agreed to a cooperative effort with Portola Pharmaceuticals to develop and commercialize andexanet alpha. Read More »
Pomerantz LLP has announced that it has filed a class action lawsuit against GW Pharmaceuticals and specific officers within the company. Read More »
Market 32 by Price Chopper has announced its recent acquisition of O’Laughlin’s Home Care Pharmacy, located in Pittsfield, Massachusetts. Read More »
A recent article in the Wall Street Journal as well as analyst commentary noted that Pfizer Inc., Amgen Inc., Allergan PLC and others have hiked up dozens of U.S. drug prices since December, with many of the increases at nearly 9 percent and 10 percent. Read More »
Pfizer recently announced it is teaming up with Adaptive Biotechnologies to help advance its growing immuno-oncology pipeline. Read More »
Pfizer Inc. announced last week that its Research and Development investment strategy will be expanded to include companies in the initial phases of scientific advancements. Read More »
Novartis Pharmaceuticals revealed this week that it is collaborating with Qualcomm Life to develop the next generation of the Breezhaler inhaler for individuals with chronic obstructive pulmonary disease (COPD). Read More »
German drugmaker Merck KGaA and U.S. drug giant Pfizer revealed this week that they are collaborating with Syndax Pharmaceuticals to investigate avelumab as a combination treatment for advanced ovarian cancer. Read More »
Pharmaceutical return services provider Guaranteed Returns recently introduced a new program that delivers quick payments to pharmacies. Read More »
Alerts Sign-up
